glycyl-arginyl-glycyl-aspartyl-seryl-proline has been researched along with am 281 in 1 studies
| Studies (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Trials (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Recent Studies (post-2010) (glycyl-arginyl-glycyl-aspartyl-seryl-proline) | Studies (am 281) | Trials (am 281) | Recent Studies (post-2010) (am 281) |
|---|---|---|---|---|---|
| 162 | 1 | 20 | 104 | 0 | 39 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahr, BA; Brown, QB; Karanian, DA; Makriyannis, A | 1 |
1 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-seryl-proline and am 281
| Article | Year |
|---|---|
Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus.
Topics: Animals; Arachidonic Acids; Cannabinoids; Dose-Response Relationship, Drug; Enzyme Activation; Female; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Hippocampus; Immunoblotting; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Oligopeptides; Organ Culture Techniques; Protein Kinases; Protein-Tyrosine Kinases; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Signal Transduction; Synapses; Time Factors | 2005 |